Study: CBD and CBG May Help Reverse Fatty Liver Disease

Understanding Fatty Liver Disease and Why It Matters

Fatty liver disease, formally known as metabolic dysfunction-associated steatotic liver disease (MASLD), affects an estimated one in four adults worldwide. The condition occurs when excess fat accumulates in liver cells, impairing the organ's ability to perform its hundreds of essential metabolic functions. Left untreated, fatty liver disease can progress to inflammation, scarring (fibrosis), cirrhosis, and ultimately liver failure.

What makes fatty liver disease particularly concerning is its strong association with the modern metabolic disease epidemic. Obesity, type 2 diabetes, insulin resistance, and poor dietary habits all contribute to fat accumulation in the liver. As rates of these conditions have climbed globally, fatty liver disease has followed, becoming the leading cause of chronic liver disease in many countries.

Current treatment options are limited. Weight loss through diet and exercise remains the primary recommendation, and only recently have pharmaceutical interventions begun to gain regulatory approval. This treatment gap has driven researchers to investigate alternative therapeutic approaches, including the potential role of cannabinoids.

How CBD and CBG Target Fatty Liver: Two Mechanisms Discovered

The Hebrew University research team identified two distinct cellular mechanisms through which CBD and CBG appear to combat fatty liver disease. Both mechanisms address fundamental breakdowns in how diseased liver cells manage energy and waste, suggesting that these cannabinoids work at a foundational metabolic level rather than merely treating symptoms.

Mechanism 1: Restoring the Liver's Backup Energy Battery

The first mechanism involves phosphocreatine, a molecule that serves as a rapid energy reserve in cells. Think of phosphocreatine as a backup battery. When cells need energy quickly and their primary power source (ATP) is depleted, phosphocreatine can donate its phosphate group to regenerate ATP almost instantly. This system is well known in muscle physiology, where it powers short bursts of intense activity, but it plays an important role in liver function as well.

In fatty liver disease, phosphocreatine levels become depleted. The liver's backup energy system essentially goes offline, leaving cells unable to respond to metabolic demands and contributing to the cascade of dysfunction that characterizes the disease.

The research team found that both CBD and CBG treatment increased phosphocreatine levels in liver cells, effectively recharging this backup energy system. With restored phosphocreatine reserves, liver cells showed improved capacity to manage metabolic stress and process the excess fat that had accumulated in the tissue.

Mechanism 2: Restarting Cellular Cleanup Through Cathepsin Activation

The second mechanism targets the lysosomal system, often described as the cell's recycling center. Lysosomes are membrane-bound organelles that break down and recycle cellular waste, damaged components, and excess materials. They accomplish this work through enzymes called cathepsins, which function like molecular scissors that cut waste products into reusable building blocks.

In fatty liver disease, cathepsin activity in lysosomes becomes suppressed. The cellular cleanup crew essentially stops working, allowing damaged proteins, lipid droplets, and other waste to accumulate. This buildup further stresses liver cells and accelerates disease progression.

CBD and CBG were found to restore cathepsin activity in lysosomes, restarting the cellular cleanup process. With functional cathepsins, liver cells could once again break down and clear the excess lipid material that defines fatty liver disease. This mechanism is particularly significant because lysosomal dysfunction has been increasingly recognized as a driver of multiple metabolic diseases, not just liver conditions.

CBG Shows Stronger Effects on Body Fat and Insulin Sensitivity

While both CBD and CBG demonstrated beneficial effects in the study, the researchers noted that CBG produced more pronounced improvements in two critical areas: body fat mass and insulin sensitivity.

CBG-treated subjects showed greater reductions in overall body fat compared to those receiving CBD. This finding is notable because excess body fat, particularly visceral fat surrounding the abdominal organs, is one of the primary drivers of fatty liver disease. Reducing body fat mass addresses one of the root causes of the condition rather than simply managing its downstream effects.

The insulin sensitivity improvements were equally significant. Insulin resistance, a condition in which cells become less responsive to insulin's signals to absorb blood sugar, is both a cause and consequence of fatty liver disease. The liver plays a central role in blood sugar regulation, and when it becomes fatty, its ability to respond to insulin deteriorates, creating a vicious cycle of worsening metabolic dysfunction.

CBG's stronger effect on insulin sensitivity suggests it may be particularly useful for individuals with fatty liver disease who also have prediabetes or type 2 diabetes, conditions that frequently co-occur. Improving insulin sensitivity can help break the metabolic dysfunction cycle and create conditions for liver recovery.

Both Cannabinoids Improved Blood Sugar and Lipid Profiles

Beyond the two primary mechanisms, the study documented broader metabolic improvements from both CBD and CBG treatment. Both compounds improved blood sugar control, helping to stabilize glucose levels and reduce the metabolic volatility that damages liver tissue over time.

Additionally, both CBD and CBG reduced levels of harmful lipids in the bloodstream. Dyslipidemia, or abnormal blood lipid levels, is a hallmark of fatty liver disease and a major risk factor for cardiovascular disease. The ability of these cannabinoids to favorably modify lipid profiles suggests benefits that extend beyond the liver itself, potentially reducing cardiovascular risk in metabolic disease patients.

These findings align with a growing body of research suggesting that cannabinoids interact with metabolic pathways in ways that are distinct from their better-known effects on pain, anxiety, and inflammation. The endocannabinoid system, which CBD and CBG modulate, has extensive involvement in metabolic regulation, including lipid metabolism, glucose homeostasis, and energy balance.

What This CBD and CBG Research Means for Cannabis Science

The Hebrew University study contributes to a rapidly expanding field of cannabinoid metabolic research. Several features of this particular study make it noteworthy within the broader scientific landscape.

First, the identification of specific cellular mechanisms moves beyond the observation that cannabinoids produce beneficial effects and begins to explain how they do so. Understanding mechanisms is essential for developing targeted therapies and predicting how cannabinoid treatments might interact with existing medications.

Second, the comparison between CBD and CBG provides valuable information about the differential effects of individual cannabinoids. Much of the early cannabis research focused on THC and CBD, but the cannabis plant produces over 100 different cannabinoids, each with potentially unique therapeutic properties. CBG, sometimes called the "mother cannabinoid" because it serves as the chemical precursor from which other cannabinoids are synthesized in the plant, has received increasing research attention in recent years.

The finding that CBG outperformed CBD in certain metabolic measures reinforces the importance of studying individual cannabinoids rather than treating cannabis-derived compounds as interchangeable. As the research base grows, clinicians may eventually be able to recommend specific cannabinoids for specific conditions based on their distinct mechanisms of action.

Current Limitations and the Road to Clinical Application

While the findings are promising, several important caveats apply. The study was conducted in preclinical models, meaning its results need to be validated in human clinical trials before therapeutic recommendations can be made. The doses used, the duration of treatment, and the specific formulations may not translate directly to human applications.

Additionally, the study does not address potential side effects or interactions with other medications commonly used by fatty liver disease patients, such as statins, diabetes medications, or blood pressure drugs. Drug interactions are a critical consideration for any new therapeutic approach, and CBD in particular is known to affect the metabolism of various pharmaceuticals through its interaction with liver enzymes in the cytochrome P450 system.

The regulatory landscape for CBD and CBG products also presents challenges. While CBD products are widely available in many markets, their quality, purity, and dosing vary enormously. Consumers interested in the potential liver health benefits of these compounds should be cautious about assuming that over-the-counter CBD or CBG supplements will deliver the same results as the controlled formulations used in laboratory research.

The Growing Case for Cannabinoids in Metabolic Health

This study fits within a broader pattern of research linking the endocannabinoid system to metabolic health. The endocannabinoid system, composed of cannabinoid receptors (CB1 and CB2), endogenous cannabinoids produced by the body, and enzymes that synthesize and break down these molecules, is now recognized as a major regulator of metabolic function.

CB1 receptors in the liver, adipose tissue, and pancreas influence fat storage, insulin secretion, and glucose metabolism. Dysregulation of the endocannabinoid system has been observed in obesity, diabetes, and metabolic syndrome, leading researchers to hypothesize that modulating this system could offer therapeutic benefits.

Plant-derived cannabinoids like CBD and CBG interact with the endocannabinoid system in complex ways that differ from the body's own endocannabinoids. Rather than simply activating or blocking cannabinoid receptors, these compounds appear to modulate the system's overall tone, potentially restoring balance in situations where the system has become dysregulated.

For the cannabis industry and the broader health and wellness sector, research like this study provides scientific grounding for the health claims that have long circulated around CBD and CBG products. As clinical evidence accumulates, it may become possible to make more specific, evidence-based recommendations about which cannabinoids are useful for which conditions, and at what doses.

The Hebrew University findings represent a meaningful step forward in understanding how two of the most commercially available and widely consumed cannabinoids interact with one of the world's most prevalent chronic diseases. Further research will determine whether these laboratory findings translate into clinical treatments that could benefit the hundreds of millions of people living with fatty liver disease worldwide.

Looking for a dispensary near you? Browse Budpedia's cannabis dispensary directory — verified shops across every legal state.